The graft‐versus‐neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms

Willems, Leen; Waer, Mark; Billiau, An

doi:10.1002/pbc.25169

Cited by 10 publications

(5 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other instance, haplo-identical stem cell transplantations consisting of alloreactive NK cells and allogeneic NK cells adoptive immunotherapy has proven effective in the treatment of AML [5]. These confirm and support the fact that NK cells are involved and play important roles in immune response against AML.…”

supporting

confidence: 56%

Acute Myeloid Leukemic Cells Express NKG2D or Shed off NKG2D Ligand to Escape Immune-Surveillance

Acheampong¹

2017

HTIJ

View full text Add to dashboard Cite

show abstract

supporting

confidence: 56%

Acute Myeloid Leukemic Cells Express NKG2D or Shed off NKG2D Ligand to Escape Immune-Surveillance

Acheampong¹

2017

HTIJ

View full text Add to dashboard Cite

show abstract

“…Although autologous HSCT remains to be the mainstay of therapy for upfront treatment in high-risk neuroblastoma based on results in the 1990s, [4] allogeneic HSCT has gained limited but increasing interest in the treatment of relapsed/refractory disease supported by the proven efficacy in hematologic malignancies and selected solid tumors. [5,6] We hereby describe the first successful report of treating post-haploidentical HSCT neuroblastoma relapse with donor lymphocyte infusion (DLI) alone, thus supporting the efficacy of graft versus tumor (GvT) effect in allogeneic HSCT for neuroblastoma treatment.…”

Section: Introductionmentioning

confidence: 80%

Remission With Donor Lymphocyte Infusion in a Child With Marrow Relapse After Haploidentical Stem Cell Transplantation for Relapsed Stage 4 Neuroblastoma

Liu

Leung

Cheuk

et al. 2016

Pediatr Blood Cancer

View full text Add to dashboard Cite

A 7-year-old male with Stage 4 neuroblastoma was treated with chemotherapy and autologous hematopoietic stem cell transplantation (HSCT), resulting in partial response with residual bone and marrow disease. He proceeded to haploidentical-HSCT with his mother as donor and achieved remission. The patient developed marrow relapse 2 years after haploidentical-HSCT with cytopenia and dropping donor chimerism. Donor lymphocyte infusion (DLI) using mother's whole blood was given resulting in clearance of marrow disease, resolution of cytopenia, and full donor chimerism. This is the first report of successful treatment for neuroblastoma relapse after haploidentical-HSCT using DLI alone, supporting the role of adoptive cell therapy post-HSCT in neuroblastoma.

show abstract

“…In mismatched SCT, NK-mediated GvL effects reduced the relapse rates in patients with leukemia. 10,25,26 We previously showed that haplo-SCT was associated with low incidence of GvHD and TRM in patients with rHR-NB. 13 However, the 5-year EFS of 19% indicated insufficient graft-versus-tumor effects.…”

Section: Discussionmentioning

confidence: 99%

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial

Flaadt

Ladenstein

Ebinger

et al. 2023

JCO

View full text Add to dashboard Cite

PURPOSE Patients with relapsed high-risk neuroblastoma (rHR-NB) have a poor prognosis. We hypothesized that graft-versus-neuroblastoma effects could be elicited by transplantation of haploidentical stem cells (haplo-SCT) exploiting cytotoxic functions of natural killer cells and their activation by the anti-GD2 antibody dinutuximab beta (DB). This phase I/II trial assessed safety, feasibility, and outcomes of immunotherapy with DB plus subcutaneous interleukin-2 (scIL2) after haplo-SCT in patients with rHR-NB. METHODS Patients age 1-21 years underwent T-/B-cell–depleted haplo-SCT followed by DB and scIL2. The primary end point ‘success of treatment’ encompassed patients receiving six cycles, being alive 180 days after end of trial treatment without progressive disease, unacceptable toxicity, acute graft-versus-host-disease (GvHD) ≥grade 3, or extensive chronic GvHD. RESULTS Seventy patients were screened, and 68 were eligible for immunotherapy. Median number of DB cycles was 6 (range, 1-9). Median number of scIL2 cycles was 3 (1−6). The primary end point was met by 37 patients (54.4%). Median observation time was 7.8 years. Five-year event-free survival (EFS) and overall survival from start of trial treatment were 43% (95% CI, 31 to 55) and 53% (95% CI, 41 to 65), respectively. Five-year EFS among patients in complete remission (CR; 52%; 95% CI, 31 to 69) or partial remission (44%; 95% CI, 27 to 60) before immunotherapy were significantly better compared with patients with nonresponse/mixed response/progressive disease (13%; 95% CI, 1 to 42; P = .026). Overall response rate in 43 patients with evidence of disease after haplo-SCT was 51% (22 patients), with 15 achieving CR (35%). Two patients developed GvHD grade 2 and 3 each. No unexpected adverse events occurred. CONCLUSION DB therapy after haplo-SCT in patients with rHR-NB is feasible, with low risk of inducing GvHD, and results in long-term remissions likely attributable to increased antineuroblastoma activity by donor-derived effector cells.

show abstract

The graft‐versus‐neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms

Cited by 10 publications

References 81 publications

Acute Myeloid Leukemic Cells Express NKG2D or Shed off NKG2D Ligand to Escape Immune-Surveillance

Acute Myeloid Leukemic Cells Express NKG2D or Shed off NKG2D Ligand to Escape Immune-Surveillance

Remission With Donor Lymphocyte Infusion in a Child With Marrow Relapse After Haploidentical Stem Cell Transplantation for Relapsed Stage 4 Neuroblastoma

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial

Contact Info

Product

Resources

About